Geens, W., Buyck, F., Raes, L., Schwarze, J. K., Awada, G., De Sutter, S., Bruneau, M., Vandemeulebroucke, J., Everaert, H., Neyns, B., & Duerinck, J. (2026). Prognostic Value of O-(2-18F-Fluoroethyl)-l-Tyrosine PET for Patients with Recurrent Glioblastoma. Journal of Nuclear Medicine, 67(4). https://doi.org/10.2967/jnumed.125.270727

@article{8396f90cc81a4dfc99d9099ff44323a8,
title = "Prognostic Value of O-(2-18F-Fluoroethyl)-l-Tyrosine PET for Patients with Recurrent Glioblastoma.",
abstract = "The determination of prognoses for patients with recurrent glioblastoma remains challenging. This study aimed to evaluate the prognostic value of static O-(2- 18F-fluoroethyl)-l-tyrosine ( 18F-FET) PET parameters in patients with recurrent glioblastoma. Methods: We retrospectively evaluated patients treated in 3 institutional clinical trials examining vascular endothelial growth factor inhibition, immune checkpoint inhibition, or their combination in recurrent glioblastoma. Patients with a baseline 18F-FET PET were included in the analysis and stratified by treatment group. Prognostic value was evaluated using univariate Kaplan-Meier and multivariate Cox regression analyses, with receiver-operating-characteristic analysis to identify optimal thresholds. Results: Both univariate and multivariate analysis revealed that patients with a larger baseline metabolic tumor volume (MTV) and higher mean tumor-to-background ratio (TBR mean) had an increased risk of death independent of treatment (MTV per 10 mL: hazard ratio, 1.06; 95\% CI, 1.01-1.12; P = 0.023; TBR mean: hazard ratio, 1.91; 95\% CI, 1.14-3.21; P = 0.014). Receiver-operating-characteristic analysis showed that an MTV and TBR mean of more than 27.94 cm 3 and 2.15, respectively, identified patients with worse overall survival in our patient population. Conclusion: Pretreatment MTV and TBR mean had a significant prognostic value in patients with recurrent glioblastoma, independent of treatment, and could be useful to stratify and select patients for future clinical trials. ",
author = "Wietse Geens and F{\'e}lix Buyck and Laurens Raes and Schwarze, \{Julia Katharina\} and Gil Awada and \{De Sutter\}, Selene and Micha{\"e}l Bruneau and Jef Vandemeulebroucke and Hendrik Everaert and Bart Neyns and Johnny Duerinck",
note = "{\textcopyright} 2026 by the Society of Nuclear Medicine and Molecular Imaging.",
year = "2026",
month = mar,
day = "26",
doi = "10.2967/jnumed.125.270727",
language = "English",
volume = "67",
journal = "Journal of Nuclear Medicine",
issn = "0161-5505",
publisher = "Society of Nuclear Medicine Inc.",
number = "4",
}